SCHEMBL3985863

SCHEMBL3985863

Cc1ccc(Cn2nc(C)c3c(c(O)c4n3CCN(C)C4=O)c2=O)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.35
PKLR P30613 1/20 0.35
ALDH1A1 P00352 1/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
LMNA P02545 1/20 0.34
TSHR P16473 2/20 0.34
TP53 P04637 2/20 0.34
HPGD P15428 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C19 P33261 1/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
PREP P48147 1/20 0.33
GAA P10253 1/20 0.32
NPBWR1 P48145 1/20 0.32
MCHR1 Q99705 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3986662 0.93 GAA (0.38) PKMPKLRALDH1A1HTTSMN1; SMN2
SCHEMBL3983532 0.92 PKM (0.44) PKMPKLRALDH1A1HTTTSHR
SCHEMBL3985461 0.92 PDE5A (0.39) HPGDMEN1KMT2AGAAMAPT
SCHEMBL3985745 0.91 NPBWR1 (0.37) PKMPKLRALDH1A1SMN1; SMN2LMNA
SCHEMBL3981492 0.89 MAOB (0.40) ALDH1A1HTTSMN1; SMN2LMNATSHR
SCHEMBL3985002 0.89 NPBWR1 (0.35) PKMPKLRLMNATP53MEN1
SCHEMBL3992564 0.88 PDE5A (0.38) ALDH1A1HTTSMN1; SMN2LMNATSHR
SCHEMBL3985346 0.87 PKM (0.36) PKMPKLRALDH1A1HTTMEN1
SCHEMBL3989304 0.86 LMNA (0.41) PKMPKLRALDH1A1HTTSMN1; SMN2
SCHEMBL3985716 0.85 PDE5A (0.46) PKMALDH1A1HTTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US claimed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US claimed
EP-1756114-B1 HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME (US) 2014-11-19 EP disclosed
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US disclosed
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287394-A1 Hiv Integrase Inhibitors DHPS, DPYD, TYMP PKM 1268/4885PKLR 519/4885ALDH1A1 913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.